JP2018508229A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508229A5 JP2018508229A5 JP2017557264A JP2017557264A JP2018508229A5 JP 2018508229 A5 JP2018508229 A5 JP 2018508229A5 JP 2017557264 A JP2017557264 A JP 2017557264A JP 2017557264 A JP2017557264 A JP 2017557264A JP 2018508229 A5 JP2018508229 A5 JP 2018508229A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- seq
- amino acid
- acid sequence
- single domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 40
- 125000003275 alpha amino acid group Chemical group 0.000 claims 17
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 16
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 230000004913 activation Effects 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000000581 natural killer T-cell Anatomy 0.000 claims 2
- VQFKFAKEUMHBLV-BYSUZVQFSA-N 1-O-(alpha-D-galactosyl)-N-hexacosanoylphytosphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCCCCCCCCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQFKFAKEUMHBLV-BYSUZVQFSA-N 0.000 claims 1
- 229930186217 Glycolipid Natural products 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2014192 | 2015-01-27 | ||
| NL2014192 | 2015-01-27 | ||
| PCT/NL2016/050064 WO2016122320A1 (en) | 2015-01-27 | 2016-01-27 | Single domain antibodies targeting cd1d |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020127379A Division JP7165701B2 (ja) | 2015-01-27 | 2020-07-28 | Ｃｄ１ｄを標的とする単一ドメイン抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018508229A JP2018508229A (ja) | 2018-03-29 |
| JP2018508229A5 true JP2018508229A5 (https=) | 2019-03-07 |
| JP6743051B2 JP6743051B2 (ja) | 2020-08-19 |
Family
ID=52630466
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557264A Active JP6743051B2 (ja) | 2015-01-27 | 2016-01-27 | Ｃｄ１ｄを標的とする単一ドメイン抗体 |
| JP2020127379A Active JP7165701B2 (ja) | 2015-01-27 | 2020-07-28 | Ｃｄ１ｄを標的とする単一ドメイン抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020127379A Active JP7165701B2 (ja) | 2015-01-27 | 2020-07-28 | Ｃｄ１ｄを標的とする単一ドメイン抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US10501541B2 (https=) |
| EP (1) | EP3250608B1 (https=) |
| JP (2) | JP6743051B2 (https=) |
| KR (2) | KR102574729B1 (https=) |
| CN (2) | CN114504645A (https=) |
| AU (2) | AU2016212777B2 (https=) |
| CA (1) | CA2975078A1 (https=) |
| EA (1) | EA201791691A1 (https=) |
| MX (1) | MX386714B (https=) |
| SG (1) | SG11201706128PA (https=) |
| WO (1) | WO2016122320A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10501541B2 (en) | 2015-01-27 | 2019-12-10 | Lava Therapeutics B.V. | Single domain antibodies targeting CD1d |
| AU2019344300A1 (en) * | 2018-09-19 | 2021-04-22 | LAVA Therapeutics N.V. | Dual acting CD1D immunoglobulin |
| WO2020113063A1 (en) * | 2018-11-30 | 2020-06-04 | Aleta Biotherapeutics Inc. | Single domain antibodies against cll-1 |
| EP3792283A1 (en) | 2019-09-16 | 2021-03-17 | Lava Therapeutics B.V. | Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies |
| EP4301374A4 (en) | 2021-03-01 | 2025-09-10 | Deciduous Therapeutics Inc | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS |
| JP2024538958A (ja) | 2021-10-21 | 2024-10-28 | ラヴァ・セラピューティクス・エヌ・ヴイ | ガンマデルタｔ細胞活性化抗体の使用 |
| CN116239687B (zh) * | 2021-12-22 | 2026-03-24 | 北京世纪沃德生物科技有限公司 | 一种crp驼源单域抗体及其制备方法和应用 |
| EP4285926A1 (en) * | 2022-05-30 | 2023-12-06 | LAVA Therapeutics N.V. | Combination treatment for chronic lymphocytic leukemia |
| EP4292610A1 (en) | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Variant antibodies that bind gamma-delta t cell receptors |
| WO2024256586A1 (en) | 2023-06-14 | 2024-12-19 | LAVA Therapeutics N.V. | Cd1d antibodies and methods of use |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2698880B1 (fr) | 1992-11-25 | 1995-02-24 | Inst Nat Sante Rech Med | Procédé de production de récepteurs T solubles, produits ainsi obtenus et leur utilisation dans des compositions diagnostiques ou thérapeutiques. |
| EP0751780B1 (en) | 1993-06-21 | 2003-09-03 | Brigham And Women's Hospital | Methods of isolating cd1-presented antigens, vaccines comprising cd1-presented antigens, and cell lines for use in said methods |
| CA2361678A1 (en) | 1999-02-05 | 2000-08-10 | Rijksuniversiteit Leiden | Method of modulating metabolite biosynthesis in recombinant cells |
| IL147920A0 (en) | 1999-08-02 | 2002-08-14 | Keygene Nv | Method for generating cgmmv resistant plants, genetic constructs, and the obtained cgmmv-resistant plants |
| US6737398B1 (en) | 1999-09-30 | 2004-05-18 | National Jewish Medical And Research Center | Modulation of γδ T cells to regulate airway hyperresponsiveness |
| WO2001022816A1 (en) | 1999-09-30 | 2001-04-05 | National Jewish Medical And Research Center | MODULATION OF ηδ T CELLS TO REGULATE AIRWAY HYPERRESPONSIVENESS |
| AU2001259230A1 (en) | 2000-04-28 | 2001-11-12 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of polyclonal b cell activation and immunoglobulin class switching topathogenic autoantibodies by blocking cd1-mediated interactions |
| JP5184732B2 (ja) | 2000-06-19 | 2013-04-17 | ベス イスラエル デアコネス メディカル センター | Ｔ細胞亜集団に特異的なモノクローナル抗体およびポリクローナル抗体の組成物および使用方法 |
| EP1372668B1 (en) | 2001-03-26 | 2011-12-07 | Dana-Farber Cancer Institute, Inc. | Method of attenuating reactions to skin irritants |
| US8178098B2 (en) | 2001-04-03 | 2012-05-15 | National Jewish Health | Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies |
| WO2003068821A2 (en) | 2002-02-14 | 2003-08-21 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
| AU2003210060B2 (en) | 2002-03-22 | 2010-02-25 | Aprogen, Inc. | Humanized antibody and process for preparing same |
| US8084020B2 (en) * | 2002-05-01 | 2011-12-27 | Beth Israel Deaconess Medical Center | Use of anti-CD1 antibodies for the modulation of immune responses |
| BRPI0315666B8 (pt) | 2002-10-23 | 2021-05-25 | Ludwig Inst For Cancer Res Ltd | dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos |
| JP2006517789A (ja) | 2003-01-10 | 2006-08-03 | アブリンクス エン．ヴェー． | 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用 |
| WO2005046711A2 (en) | 2003-11-07 | 2005-05-26 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Stimulation or inhibition of gamma delta t-cells to promote or inhibit bone healing |
| CA2569509C (en) | 2004-06-03 | 2014-08-12 | Novimmune S.A. | Anti-cd3 antibodies and methods of use thereof |
| DE602005022728D1 (de) | 2004-08-19 | 2010-09-16 | Univ Cardiff | Präparation antigenpräsentierender menschlicher gamma delta t-zellen und verwendung in der immuntherapie |
| WO2006060117A2 (en) | 2004-11-02 | 2006-06-08 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for inhibition of nkt cells |
| US8338173B2 (en) | 2005-08-11 | 2012-12-25 | University College Cardiff Consultants Limited | Preparation of antigen-presenting human γδ T cells and use in immunotherapy |
| JP5672647B2 (ja) * | 2006-02-22 | 2015-02-18 | 独立行政法人理化学研究所 | ＣＤ１ｄリガンドをパルスした、標的抗原及びＣＤ１ｄの共発現細胞による免疫療法 |
| GB0605247D0 (en) * | 2006-03-15 | 2006-04-26 | Chiron Srl | Compositions and methods for immunisation |
| EP1878440A1 (en) | 2006-07-13 | 2008-01-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds |
| US8012484B2 (en) | 2007-04-12 | 2011-09-06 | University Of Virginia Patent Foundation | Method of treating ischemia reperfusion injury by inhibiting NKT cell activity |
| EP2058388A1 (en) * | 2007-10-05 | 2009-05-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Non-conventional NKT cells for use in cancer therapy |
| WO2010130830A2 (en) * | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders |
| SG11201400521PA (en) * | 2011-10-14 | 2014-08-28 | Teva Pharmaceuticals Australia Pty Ltd | ANTIBODIES TO CD1d |
| US9670275B2 (en) | 2012-01-23 | 2017-06-06 | Ablynx N.V. | Sequences directed against hepatocyte growth factor (HGF) and polypeptides comprising the same for the treatment of cancers and/or tumors |
| CN104334741B (zh) | 2012-03-28 | 2018-08-17 | 歌德塔有限公司 | 组合的γ9δ2T细胞受体链交换 |
| WO2013174403A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2013174404A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014127785A1 (en) | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| US20170029454A1 (en) | 2013-06-28 | 2017-02-02 | The Scripps Research Institute | Nkt cell ligands and methods of use |
| DK3105252T3 (da) | 2014-02-12 | 2019-10-14 | Michael Uhlin | Bispecifikke antistoffer til anvendelse ved stamcelletransplantation |
| DK3129404T3 (da) | 2014-04-10 | 2026-04-20 | Lava Therapeutics N V | Immunglobuliner, der binder humane vgamma9vdelta2-t-cellereceptorer |
| MX2016014434A (es) | 2014-05-13 | 2017-02-23 | Chugai Pharmaceutical Co Ltd | Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion. |
| CA2988504A1 (en) | 2014-07-02 | 2016-01-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods for diagnosing and treating cd1d restricted gamma/delta t cell lymphomas |
| IL297773B2 (en) | 2014-11-17 | 2024-07-01 | Adicet Bio Inc | Engineered gamma delta t-cells |
| US10501541B2 (en) | 2015-01-27 | 2019-12-10 | Lava Therapeutics B.V. | Single domain antibodies targeting CD1d |
| CN104829730A (zh) | 2015-04-14 | 2015-08-12 | 苏静 | 一种能联合免疫细胞增强肿瘤杀伤能力的双特异性抗体及其制备方法和应用 |
| US11000603B2 (en) | 2015-04-14 | 2021-05-11 | Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. | Multi-specific binding conjugate, related pharmaceutical compositions and use |
| WO2017086367A1 (ja) | 2015-11-18 | 2017-05-26 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法 |
| CN109195992A (zh) | 2016-04-29 | 2019-01-11 | 本康生物制药（深圳）有限公司 | 多特异性结合偶联物、相关的药物组合物及应用 |
| US20180028566A1 (en) | 2016-07-29 | 2018-02-01 | New York University | Gamma delta t cells as a target for treatment of solid tumors |
| US20190336615A1 (en) | 2017-01-27 | 2019-11-07 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| WO2018229163A1 (en) | 2017-06-14 | 2018-12-20 | King's College London | Methods of activating v delta 2 negative gamma delta t cells |
| TWI687227B (zh) | 2017-10-03 | 2020-03-11 | 生倍科技股份有限公司 | 用於t細胞免疫療法之組合及其用途 |
| WO2019195535A1 (en) | 2018-04-05 | 2019-10-10 | Novartis Ag | Trispecific binding molecules against cancers and uses thereof |
| CA3105448A1 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| EP3927431A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| MA55903A (fr) | 2019-05-08 | 2022-03-16 | Janssen Biotech Inc | Matières et méthodes pour moduler l'immunité médiée par les lymphocytes t |
| JP2022545196A (ja) | 2019-08-16 | 2022-10-26 | ガンマデルタ セラピューティクス リミテッド | 抗ｔｃｒデルタ可変１抗体の治療的使用 |
| JP7764364B2 (ja) | 2019-08-16 | 2025-11-05 | ガンマデルタ セラピューティクス リミティッド | エクスビボγδ Ｔ細胞集団 |
| AU2021225870A1 (en) | 2020-02-27 | 2022-10-20 | Janssen Biotech, Inc. | Materials and methods for modulating an immune response |
| IL296358A (en) | 2020-03-13 | 2022-11-01 | Janssen Biotech Inc | Materials and methods for modulating delta chain mediated immunity |
| EP4237003A4 (en) | 2020-10-28 | 2025-07-09 | Janssen Biotech Inc | COMPOSITIONS AND METHODS FOR MODULATING GAMMA DELTA CHAIN-MEDIATED IMMUNITY |
-
2016
- 2016-01-27 US US15/546,406 patent/US10501541B2/en active Active
- 2016-01-27 MX MX2017009680A patent/MX386714B/es unknown
- 2016-01-27 WO PCT/NL2016/050064 patent/WO2016122320A1/en not_active Ceased
- 2016-01-27 EP EP16715360.0A patent/EP3250608B1/en not_active Revoked
- 2016-01-27 KR KR1020177024072A patent/KR102574729B1/ko active Active
- 2016-01-27 JP JP2017557264A patent/JP6743051B2/ja active Active
- 2016-01-27 CN CN202111671891.XA patent/CN114504645A/zh active Pending
- 2016-01-27 SG SG11201706128PA patent/SG11201706128PA/en unknown
- 2016-01-27 EA EA201791691A patent/EA201791691A1/ru unknown
- 2016-01-27 CN CN201680007612.0A patent/CN107531787B/zh not_active Withdrawn - After Issue
- 2016-01-27 AU AU2016212777A patent/AU2016212777B2/en not_active Revoked
- 2016-01-27 KR KR1020237029643A patent/KR20230132604A/ko active Pending
- 2016-01-27 CA CA2975078A patent/CA2975078A1/en active Pending
-
2019
- 2019-10-29 US US16/666,734 patent/US11591394B2/en active Active
-
2020
- 2020-07-28 JP JP2020127379A patent/JP7165701B2/ja active Active
-
2022
- 2022-02-11 AU AU2022200922A patent/AU2022200922A1/en not_active Withdrawn
-
2023
- 2023-01-30 US US18/161,163 patent/US12110328B2/en active Active
-
2024
- 2024-09-03 US US18/822,745 patent/US20240425592A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018508229A5 (https=) | ||
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| RU2016129517A (ru) | Биспецифические антитела к her2 и способы применения | |
| CO2018013500A2 (es) | Anticuerpos anti-pd-l1 y usos de los mismos | |
| BR112019012040A2 (pt) | anticorpo isolado ou fragmento do mesmo, composição, célula isolada, e, métodos para tratamento de câncer, para detecção da expressão de cd73 em uma amostra e para identificação de um paciente com câncer adequado para o tratamento com uma terapia anti-cd73. | |
| CO2018005932A2 (es) | Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas | |
| JP2013502204A5 (https=) | ||
| JP2013538796A5 (https=) | ||
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| CY1121249T1 (el) | Αντισωμα εναντι του ειδικου προστατικου αντιγονου βλαστικου κυτταρου και χρησεις αυτου | |
| JP2018527919A5 (https=) | ||
| HK1257730A1 (zh) | 抗despr单克隆抗体用於癌症和中风的靶向疗法及成像 | |
| UA105009C2 (uk) | Композиції та способи, призначені для спрямованого впливу антитіл на білок с5 системи комплементу | |
| BR112017019785A2 (pt) | anticorpos terapêuticos e seus usos | |
| JP2015143226A5 (https=) | ||
| EA201591131A1 (ru) | Днк-конструкции антитела и способ их применения | |
| HRP20161656T4 (hr) | Sredstva za vezanje na cd33 | |
| RU2014101707A (ru) | АНТИ-Axl АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ | |
| MX2014008963A (es) | Moleculas de anticuerpos biespecificos con celulas t transfectadas por antigeno y su uso en medicina. | |
| EP4477270A3 (en) | Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells | |
| RU2017107773A (ru) | Антитела, специфичные к ммр9 | |
| Naidoo et al. | Nanobodies enhancing cancer visualization, diagnosis and therapeutics | |
| RU2017111584A (ru) | Антитело против злокачественной клетки, противораковое лекарственное средство и способ тестирования злокачественного новообразования | |
| BR112017027702A2 (pt) | anticorpos antirreceptor do fator de crescimento endotelial vascular 2 (vegfr2) | |
| EA202191658A1 (ru) | Антитела против фактора c2b комплемента человека и способы применения |